Breast Cancer Foundation NZ
Development of inhibitors as anti-cancer therapeutics
April 2017
Research Grant
What is the problem and who is affected?
For many patients, once the breast cancer has gone metastatic, when it has spread beyond the breast, conventional chemotherapy is no longer effective. This means that, for now, advanced breast cancer is a terminal diagnosis.
What is this research hoping to achieve?
Dr Barker and his team aim to develop drugs that will target an enzyme, phosphatidylcholine-specific phospholipase C (PC-PLC), that facilitates the spreading of tumours in triple negative breast cancer. If they are able to inhibit PC-PLC, the tumour shouldn't be able to spread and chemotherapy should still work.
Funding was provided by a tripartite partnership with BCFNZ, the Health Research Council of New Zealand (HRC) and Breast Cancer Cure (BCC).
-
JuneResearch Grant
Helping surgeons accurately locate breast tumours
-
JuneResearch Grant
New sugar-based drug to stop breast cancer spreading
-
JuneResearch Grant
A personalized vaccine for breast cancer
-
JuneResearch Grant
A simpler way to check for the spread of breast cancer
-
JuneResearch Grant
A new way to treat breast cancers
-
AprilResearch Grant
Development of inhibitors as anti-cancer therapeutics
-
AprilResearch Grant
The potential of immunotherapy as a treatment for ER+ breast cancer
-
AprilResearch Grant
Targeting growth hormone signal transduction in breast cancer
-
MarchResearch Grant
Five-year research partnership targets breast cancer vaccine
-
FebruaryBelinda Scott Fellowship
Benefits of an integrated tai chi programme in breast cancer